• Clinical Insights: November 13, 2017

    Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval Heplisav-B [Hepatitis B Vaccine, Recombinant (Adjuvanted)] – New Vaccine Approval – November 9, 2017 – Dynavax Technologies Corporation announced that the U.S. Food and Drug Administration… Read more »

  • November 2017 – 340B Insider

    Welcome to the November edition of RxStrategies’ 340B Insider, a concise communication to provide a quick highlight of updates from RxStrategies’ view. 340B INDUSTRY NEWS CMS UPDATE: Final Regulation Cuts Nearly 30 Percent in Medicare Part B Drug Payments to 340B Hospitals As you are aware, Centers for Medicare & Medicaid Services (CMS) published on 11/1/17,… Read more »

  • Clinical Insights: October 24, 2017

    Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval Shingrix (Zoster Vaccine Recombinant, Adjuvanted) – New Vaccine Approval – October 20, 2017 – GlaxoSmithKline plc announced that the U.S. Food and Drug Administration (FDA) has… Read more »

  • October 2017 – 340B Insider

    Welcome to the October edition of RxStrategies’ 340B Insider, a concise communication to provide a quick highlight of updates from RxStrategies’ view.    340B INDUSTRY NEWS UPDATE: HOUSE ENERGY & COMMERCE OVERSIGHT SUBCOMMITTEE HEARING On October 11, the House Energy & Commerce (E&C) oversight subcommittee held a second hearing on the 340B program, focusing on how Covered… Read more »

  • Clinical Insights: October 16, 2017

    Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval No new updates.   New Formulation Approval Lyrica® CR (pregabalin) – October 12, 2017 – Pfizer Inc. announced that the United States Food and Drug Administration… Read more »

  • Clinical Insights: October 10, 2017

    Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval Zilretta™ (triamcinolone acetonide extended-release) – October 6, 2017 – Flexion Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) approved Zilretta™ (triamcinolone acetonide extended-release… Read more »

  • Clinical Insights: October 2, 2017

    Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval Verzenio™ (abemaciclib) – September 28, 2017 – The U.S. Food and Drug Administration approved Verzenio™ (abemaciclib) to treat adult patients who have hormone receptor (HR)-positive, human epidermal growth… Read more »

  • Clinical Insights: September 22, 2017

    Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval Solosec™ (secnidazole) – September 18, 2017 – Symbiomix Therapeutics announced the U.S. Food and Drug Administration (FDA) has approved Solosec™ (secnidazole) 2g oral granules for the… Read more »

  • Clinical Insights: September 15, 2017

    Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval Aliqopa™ (copanlisib) – September 14, 2017 – The U.S. Food and Drug Administration granted accelerated approval to Aliqopa™ (copanlisib) for the treatment of adults with relapsed… Read more »

  • Temporary Corporate Office Closure Due To Hurricane Irma

    RxStrategies’ corporate office is based in South Florida, and as such, the area is recovering from the impact of Hurricane Irma.  As local authorities work to clear roadways and restore power to the area, RxStrategies’ corporate office will remain closed on Wednesday, September 13. We will continue to keep you updated regarding when the corporate office will be operational.… Read more »